Although some studies in AD animal models show that IGF-1 treatment reduces Aβ accumulation and improves behavioral and pathological AD, the therapeutic strategy targeting increasing circulating IGF-1 failed to delay AD progression in a clinical trial [240]. Here, IGF1 is linked to Alzheimer disease.